Advertisement

International Journal of Hematology

, Volume 109, Issue 5, pp 545–552 | Cite as

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

  • Koji Sasaki
  • Hagop M. Kantarjian
  • Susan O’Brien
  • Farhad Ravandi
  • Marina Konopleva
  • Gautam Borthakur
  • Guillermo Garcia-Manero
  • William G. Wierda
  • Naval Daver
  • Alessandra Ferrajoli
  • Koichi Takahashi
  • Preetesh Jain
  • Mary Beth Rios
  • Sherry A. Pierce
  • Elias J. Jabbour
  • Jorge E. CortesEmail author
Original Article

Abstract

Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014. Patients who had prior history of cancer, a concurrent diagnosis of other malignancies in the same diagnostic year, or a second leukemia after CML diagnosis were excluded. Second malignancies were observed in 597 patients (4%) with a median follow-up of 69 months. The 5- and 10-year cumulative incidences of death for all patients were 30.5% and 41.8%. The 5- and 10-year cumulative incidences of second malignancies were 4.4% and 7.2%, respectively. The overall standardized incidence ratio (SIR) was 1.204. Increased SIRs compared to the general population were observed for the male genital system, 1.593; digestive system, 1.291; skin, 1.588; and urinary system, 1.366. Overall excess absolute risk was 1.714 per 1000 person-years at risk. Our results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.

Keywords

Chronic myeloid leukemia Tyrosine kinase inhibitor Second malignancies 

Notes

Acknowledgements

This study was partly supported by the National Institutes of Health/National Cancer Institute under Award Number P30 CA016672 and Award Number P01 CA049639. We also acknowledge the Department of Scientific Publications for editorial assistance.

Author contributions

KS collected data, designed the study, analyzed the data and wrote the manuscript. HMK, SO’B, FR, MK, GB, GGM, WGW, ND, AF, KT, PJ, MBR, SAP, and EJJ edited the manuscript. JEC designed the study, analyzed the data, and edited the manuscript. All authors provided significant intellectual input and reviewed and approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

HMK received research grants from Novartis, Bristol-Myers Squibb, Pfizer, and Ariad. FR received research funding from Novartis and Bristol-Myers Squibb. EJJ received consultancy fees from Ariad, Bristol-Myers Squibb, Teva, and Pfizer. JEC received research support from Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva and is a consultant for Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. KS, SO’B, MK, GB, GGM, WGW, ND, AF, KT, PJ, MBR, and SAP declare that they have no relevant conflict of interest.

References

  1. 1.
    Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7.CrossRefGoogle Scholar
  2. 2.
    Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.CrossRefGoogle Scholar
  3. 3.
    Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.CrossRefGoogle Scholar
  4. 4.
    Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27.CrossRefGoogle Scholar
  5. 5.
    Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.CrossRefGoogle Scholar
  6. 6.
    Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2(3):e118-28.CrossRefGoogle Scholar
  7. 7.
    Kantarjian HM, Talpaz M, O’Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108(6):1835–40.CrossRefGoogle Scholar
  8. 8.
    Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-93.Google Scholar
  9. 9.
    Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30(6):1255–62.CrossRefGoogle Scholar
  10. 10.
    Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol. 2015;169(5):683–8.CrossRefGoogle Scholar
  11. 11.
    Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118(16):4353–8.CrossRefGoogle Scholar
  12. 12.
    Shah BK, Ghimire KB. Second primary malignancies in chronic myeloid leukemia. Indian J Hematol Blood Transfus. 2014;30(4):236–40.CrossRefGoogle Scholar
  13. 13.
    Ahmed F, Goodman MT, Kosary C, Ruiz B, Wu XC, Chen VW, et al. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975–2001. Cancer. 2006;107(5 Suppl):1162–71.CrossRefGoogle Scholar
  14. 14.
    National Cancer Institute: Surveillance E, and End results Program. Cancer Stat facts: leukemia—chronic myeloid leukemia (CML). 2018. https://seer.cancer.gov/statfacts/html/cmyl.html.
  15. 15.
    Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016;122(2):238–48.CrossRefGoogle Scholar
  16. 16.
    Dahlen T, Edgren G, Lambe M, Hoglund M, Bjorkholm M, Sandin F, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165(3):161–6.CrossRefGoogle Scholar
  17. 17.
    Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5):625–32.CrossRefGoogle Scholar
  18. 18.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefGoogle Scholar
  19. 19.
    Kumar V, Garg M, Chaudhary N, Chandra AB. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ. 2018;6:e4342.CrossRefGoogle Scholar
  20. 20.
    Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, et al. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018;35(7):99.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Koji Sasaki
    • 1
  • Hagop M. Kantarjian
    • 1
  • Susan O’Brien
    • 1
    • 2
  • Farhad Ravandi
    • 1
  • Marina Konopleva
    • 1
  • Gautam Borthakur
    • 1
  • Guillermo Garcia-Manero
    • 1
  • William G. Wierda
    • 1
  • Naval Daver
    • 1
  • Alessandra Ferrajoli
    • 1
  • Koichi Takahashi
    • 1
  • Preetesh Jain
    • 1
  • Mary Beth Rios
    • 1
  • Sherry A. Pierce
    • 1
  • Elias J. Jabbour
    • 1
  • Jorge E. Cortes
    • 1
    Email author
  1. 1.Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.University of California, Irvine, Chao Family Comprehensive Cancer CenterOrangeUSA

Personalised recommendations